Akeso Biopharma Placement (9926.HK) - The Concerns Behind and the Outlook

574 Views11 Jul 2022 08:59
Akeso’s conservative style/development mode/low cash balance and FDA’s “Guidance” on bispecific antibody will limit its outlook and valuation expansion. The Placing won’t bring any fundamental change.
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
(Paid Plans Only)